3-溴-4-异丙基苯甲酸甲酯 | 318528-55-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 3-溴-4-异丙基苯甲酸甲酯
• 英文名称: 3-bromo-4-(1-methylethyl)-benzoic acid methyl ester
• 英文别名: methyl-3-bromo-4-isopropylbenzoate；Methyl 3-bromo-4-isopropylbenzoate；methyl 3-bromo-4-propan-2-ylbenzoate
• CAS: 318528-55-1
• 化学式: C₁₁H₁₃BrO₂
• 分子量: 257.127
• InChiKey: KVBRRJZVELPSOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2916399090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  3-溴-4-异丙基苯甲酸甲酯 在 lithium aluminium tetrahydride 、 四(三苯基膦)钯 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 3-cyano-4-isopropylbenzyl alcohol
  参考文献：
  名称：

  [EN] SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-b]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS
  [FR] DÉRIVÉS 4,5,6,7-TÉTRAHYDRO-PYRAZOLO[1,5-A]PYRIMIDINE ET DÉRIVÉS 2,3-DIHYDRO-1H-IMIDAZO[1,2-B]PYRAZOLE SUBSTITUÉS COMME INHIBITEURS DE ROS1

  摘要：

  本发明涉及式(I)的取代的4,5,6,7-四氢吡唑并[1,5-a]嘧啶衍生物和2,3-二氢-1H-咪唑并[1,2-b]吡唑衍生物，以及式(I')的化合物，其中变量具有权利要求中定义的含义。根据本发明的化合物可作为ROS1抑制剂使用。本发明还涉及制备此类新颖化合物的方法、包含所述化合物作为活性成分的药物组合物，以及所述化合物作为药物的用途。

  公开号：

  WO2015144801A1

文献信息

• [EN] SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-b]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS<br/>[FR] DÉRIVÉS 4,5,6,7-TÉTRAHYDRO-PYRAZOLO[1,5-A]PYRIMIDINE ET DÉRIVÉS 2,3-DIHYDRO-1H-IMIDAZO[1,2-B]PYRAZOLE SUBSTITUÉS COMME INHIBITEURS DE ROS1
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2015144801A1

  公开（公告）日：2015-10-01

  The present invention relates to substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives of formula (I) and also compounds of formula (I') wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as ROS1 inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及式(I)的取代的4,5,6,7-四氢吡唑并[1,5-a]嘧啶衍生物和2,3-二氢-1H-咪唑并[1,2-b]吡唑衍生物，以及式(I')的化合物，其中变量具有权利要求中定义的含义。根据本发明的化合物可作为ROS1抑制剂使用。本发明还涉及制备此类新颖化合物的方法、包含所述化合物作为活性成分的药物组合物，以及所述化合物作为药物的用途。
• Novel compounds
  申请人：SmithKline Beecham p.l.c.

  公开号：US20030036551A1

  公开（公告）日：2003-02-20

  1 Compounds of formula (I) wherein Q is a monocyclic or bicyclic aryl or heteroaryl ring; R 1 is hydrogen; R 2 is hydrogen or up to three substituents selected from halogen, NO 2 , CN, N 3 , CF 3 O—, CF 3 S—, CF 3 SO 2 —, CF 3 CO—, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, C 1-6 perfluoroalkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-C 1-4 alkyl-, C 1-6 alkylO—C 1-6 alkylCO—, C 3-6 cycloalkylO—, C 3-6 cycloalkylCO—, C 3-6 cycloalkyl-C 1-4 alkylO—, C 3-6 cycloalkyl-C 1-4 alkylCO—, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C 1-4 alkyl-, C 1-6 alkylS—, C 1-6 alkylSO 2 —, (C 1-4 alkyl) 2 NSO 2 —,(C 1-4 alkyl)NHSO 2 —, (C 1-4 alkyl) 2 NCO—, (C 1-4 alkyl)NCHO—, or CONH 2 , or —NR 3 R 4 where R 3 is hydrogen or C 1-4 alkyl, and R 4 is hydrogen, C 1-4 alkyl, formyl, —CO 2 C 1-4 alkyl, or —COC 1-4 alkyl, or two R 2 groups together form a carbocyclic ring that is saturated or unsaturated and unsubstituted or substituted by —OH or ═O; X is halogen, C 1-6 alkoxy, C 1-6 alkyl, or C 1-6 perfluoroalkyl, and; Y is hydrogen, halogen, C 1-6 alkoxy, C 1-6 alkyl, or C 1-6 perfluoroalkyl; but excluding the compounds N-(5-Iodo-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-azidobenzamide and N-(5-iodo-1,2,3,4-tetrahydroiso-quinolin-7-yl)-5-benzoyl-2-methoxybenzamide; and pharmaceutically acceptable salts or solvates thereof possess anticonvulsant activity and are useful in the treatment of a variety of disorders.

  化合物的公式为（I），其中Q是单环或双环芳基或杂环芳基环；R1为氢；R2为氢或最多三个取自卤素、NO2、CN、N3、CF3O-、CF3S-、CF3SO2-、CF3CO-、C1-6烷基、C1-6烯基、C1-6炔基、C1-6全氟烷基、C3-6环烷基、C3-6环烷基-C1-4烷基-、C1-6烷基O-C1-6烷基CO-、C3-6环烷基O-、C3-6环烷基CO-、C3-6环烷基-C1-4烷基O-、C3-6环烷基-C1-4烷基CO-、苯基、苯氧基、苄氧基、苯甲酰基、苯基-C1-4烷基-、C1-6烷基S-、C1-6烷基SO2-、（C1-4烷基）2NSO2-、（C1-4烷基）NHSO2-、（C1-4烷基）2NCO-、（C1-4烷基）NCHO-或CONH2，或—NR3R4，其中R3为氢或C1-4烷基，R4为氢、C1-4烷基、甲酰基、—CO2C1-4烷基或—COC1-4烷基，或两个R2基组成一个饱和或不饱和的碳环，未取代或被—OH或═O取代；X为卤素、C1-6烷氧基、C1-6烷基或C1-6全氟烷基；Y为氢、卤素、C1-6烷氧基、C1-6烷基或C1-6全氟烷基；但不包括N-(5-碘-1,2,3,4-四氢异喹啉-7-基)-4-叠氮苯甲酰胺和N-(5-碘-1,2,3,4-四氢异喹啉-7-基)-5-苯甲酰基-2-甲氧基苯甲酰胺；其药学上可接受的盐或溶剂化合物具有抗癫痫活性，并可用于治疗多种疾病。
• Isoquinolinyl carboxamides and their use as anticonvulsants
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1367055A1

  公开（公告）日：2003-12-03

  Compounds of formula (I): wherein Q is a monocyclic or bicyclic aryl or heteroaryl ring; R1 is hydrogen; R2 is hydrogen or up to three substituents selected from halogen, NO2, CN, N3, CF3O-, CF3S-, CF3SO2-, CF3CO-, C1-6alkyl, C1-6alkenyl, C1-6alkynyl, C1-6perfluoroalkyl, C3-6cycloalkyl, C3-6cycloalkyl-C1-4alkyl-, C1-6alkylO-, C1-6alkylCO-, C3-6cycloalkylO-, C3-6cycloalkylCO-,C3-6cycloalkyl-C1-4alkylO-, C3-6cycloalkyl-C1-4alkylCO-, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C1-4alkyl-, C1-6alkylS-, C1-6alkylSO2-, (C1-4alkyl)2NSO2-, (C1-4alkyl)NHSO2-, (C1-4alkyl)2NCO-, (C1-4alkyl)NHCO-, or CONH2, or -NR3R4 where R3 is hydrogen or C1-4 alkyl, and R4 is hydrogen, C1-4alkyl, formyl, -CO2C1-4alkyl, or -COC1-4alkyl, or two R2 groups together form a carbocyclic ring that is saturated or unsaturated and unsubstituted or substituted by -OH or =O; X is halogen, C1-6 alkoxy, C1-6 alkyl, or C1-6 perfluoroalkyl, and; Y is hydrogen, halogen, C1-6 alkoxy, C1-6 alkyl, or C1-6 perfluoroalkyl; but excluding the compounds N-(5-Iodo-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-azidobenzamide and N-(5-iodo-1,2,3,4-tetrahydroisoquinolin-7-yl)-5-benzoyl-2-methoxybenzamide; and pharmaceutically acceptable salts or solvates thereof possess anticonvulsant activity and are useful in the treatment of a variety of disorders.

  式(I)化合物： 其中 Q 是单环或双环芳基或杂芳基环； R1 是氢 C1-6烷基CO-、C3-6环烷基O-、C3-6环烷基CO-、C3-6环烷基-C1-4烷基O-、C3-6环烷基-C1-4烷基CO-、苯基、苯氧基、苄氧基、苯甲酰基、苯基-C1-4烷基、C1-6烷基S-、C1-6烷基SO2-、(C1-4烷基)2NSO2-、 (C1-4烷基)NHSO2-，(C1-4烷基)2NCO-，(C1-4烷基)NHCO-，或 CONH2，或-NR3R4，其中 R3 是氢或 C1-4 烷基，R4 是氢、C1-4烷基、甲酰基、-C2C1-4烷基或-COC1-4烷基，或两个 R2 基团共同形成饱和或不饱和且未被取代或被-OH 或 =O 取代的碳环； X 是卤素、C1-6 烷氧基、C1-6 烷基或 C1-6 全氟烷基，以及 Y 是氢、卤素、C1-6 烷氧基、C1-6 烷基或 C1-6 全氟烷基； 但不包括化合物 N-(5-碘-1,2,3,4-四氢异喹啉-7-基)-4-叠氮苯甲酰胺和 N-(5-碘-1,2,3,4-四氢异喹啉-7-基)-5-苯甲酰基-2-甲氧基苯甲酰胺； 及其药学上可接受的盐或溶液具有抗惊厥活性，可用于治疗多种疾病。
• Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors
  申请人：Janssen Pharmaceutica NV

  公开号：US10280170B2

  公开（公告）日：2019-05-07

  The present invention relates to substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives of formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as ROS1 inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及式 (I) 的取代的 4,5,6,7-四氢吡唑并[1,5-a]吡嗪衍生物和 5,6,7,8-四氢-4H-吡唑并[1,5-a][1,4]二氮杂卓衍生物 其中的变量具有权利要求中定义的含义。根据本发明的化合物可用作 ROS1 抑制剂。本发明进一步涉及制备此类新型化合物的工艺、包含所述化合物作为活性成分的药物组合物以及所述化合物作为药物的用途。
• Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors
  申请人：Janssen Pharmaceutica NV

  公开号：US10342795B2

  公开（公告）日：2019-07-09

  The present invention relates to substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives of formula (I) and also compounds of formula (I′) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as ROS1 inhibitors. The invention further relates to processes for preparing novel compounds of the present invention, pharmaceutical compositions comprising compounds of the present invention as an active ingredient as well as the use of compounds of the present invention as a medicament.

  本发明涉及式 (I) 的取代的 4,5,6,7-四氢吡唑并[1,5-a]嘧啶衍生物和 2,3-二氢-1H-咪唑并[1,2-b]吡唑衍生物 以及式（I′）化合物 其中的变量具有权利要求中定义的含义。根据本发明的化合物可用作 ROS1 抑制剂。本发明进一步涉及制备本发明新型化合物的工艺、包含本发明化合物作为活性成分的药物组合物以及本发明化合物作为药物的用途。